Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28735247 | 0.80 | LMNA (0.40) | FPR2LMNAADORA2BESR1SMN1; SMN2 | |
| SCHEMBL12636575 | 0.79 | FPR2 (0.46) | FPR2LMNAALDH1A1KMT2AKDM4E | |
| SCHEMBL11250299 | 0.76 | KMT2A (0.36) | LMNASMN1; SMN2ALDH1A1KMT2APOLB | |
| SCHEMBL30765892 | 0.75 | LMNA (0.49) | LMNAALDH1A1KMT2APOLBMAPT | |
| SCHEMBL29068022 | 0.73 | GRM2 (0.43) | ADORA2BALDH1A1KMT2APOLB | |
| SCHEMBL2503280 | 0.73 | FPR2 (0.39) | FPR2LMNAESR1SMN1; SMN2CSNK2A2 | |
| SCHEMBL938206 | 0.72 | ARG1 (0.53) | FPR2LMNAESR1SMN1; SMN2CSNK2A2 | |
| SCHEMBL369240 | 0.72 | ALPL (0.54) | ESR1SMN1; SMN2ALDH1A1KMT2AKDM4E | |
| SCHEMBL4288735 | 0.72 | FPR2 (0.40) | FPR2LMNAESR1SMN1; SMN2CSNK2A2 | |
| SCHEMBL15501010 | 0.72 | CSNK2A2 (0.46) | FPR2LMNAESR1SMN1; SMN2CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541580-B2 | Process for the preparation of pyrazinone thrombin inhibitor and its intermediates | DIAKRON PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2496087-A1 | PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES | Diakron Pharmaceuticals, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011056806-A1 | PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES | DIAKRON PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105753-A1 | PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES | DIAKRON PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105753-A1 | PROCESS FOR THE PREPARATION OF PYRAZINONE THROMBIN INHIBITOR AND ITS INTERMEDIATES | TFPI, TFPI2, F2 | FPR2 678/4885LMNA 1162/4885ADORA2B 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.